MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ygyno.2025.10.022

Медицинская библиотека · Gynecologic oncology · 2025

Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.

Lindgren Auni, Benseler Anouk, Hogen Liat, May Taymaa, Laframboise Stephane, Ferguson Sarah E, Bouchard-Fortier Genevieve, Avery Lisa, Bernardini Marcus Q

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To investigate the association of adjuvant intraperitoneal (IP) and intravenous (IV) chemotherapy with location and timing of recurrence in patients with advanced high grade serous ovarian cancer (HGSOC).

METHODS

This retrospective cohort study includes patients with stage III or IV HGSOC who underwent optimal primary cytoreductive surgery (PCS) and subsequently received paclitaxel and platinum-based chemotherapy, either IP or IV, at a tertiary care institution between 2010 and 2020. We performed adjusted multivariable logistic regressions to evaluate locations of first recurrence, and adjusted Cox proportional hazards models to assess the association of adjuvant chemotherapy administration and progression free survival.

RESULTS

208 patients met inclusion criteria, of whom 152 (73 %) received IP and 56 (27 %) received IV chemotherapy. IP chemotherapy was associated with decreased intraperitoneal recurrence (odds radio (OR) 0.33 (95 % confidence interval (CI) 0.17-0.64). Extraperitoneal disease at diagnosis was the only factor associated with increased extraperitoneal recurrence (OR 4.09 (95 % CI 1.84-9.10)). Presence of lymph node disease at diagnosis and gross residual disease at PCS were associated with increased lymph node recurrence (OR 4.54 (95 %CI 2.35-9.04) and OR 2.43 (95 %CI 1.18-5.11) respectively). After two years, the risk of recurrence was lower for patients who received IP, compared with IV, chemotherapy (HR 0.30 (95 % CI 0.17-0.53)).

CONCLUSIONS

For patients with HGSOC after optimal PCS, IP chemotherapy is associated with decreased intraperitoneal recurrence and decreased risk of recurrence after 2 years compared with IV chemotherapy. This highlights its value in peritoneal restricted disease.

Для цитирования: Lindgren Auni, Benseler Anouk, Hogen Liat, May Taymaa, Laframboise Stephane, Ferguson Sarah E, Bouchard-Fortier Genevieve, Avery Lisa, Bernardini Marcus Q. Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.. Gynecologic oncology. 2025. DOI: 10.1016/j.ygyno.2025.10.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.